Drugs that contain Cariprazine Hydrochloride
1. List of Vraylar drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7943621 | ALLERGAN | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(5 years from now) | |
| US7737142 | ALLERGAN | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47350 | ALLERGAN | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(6 years from now) | |
| USRE49110 | ALLERGAN | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | May 24, 2022 |
Market Authorisation Date: 17 September, 2015
Treatment: Treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; Treatment of schizophrenia with cariprazine; Treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine
Dosage: CAPSULE;ORAL
How can I launch a generic of VRAYLAR before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic